Follow The Filings

VNDA Vanda Pharmaceuticals Inc.

Health Care, filed as VANDA PHARMACEUTICALS INC (COM), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

  • 2 Owners
  • Max 2.7%
  • $7.4M
  • 1 reduce

In 2026 Q2 Murray Stahl trimmed Vanda Pharmaceuticals.

Who owns this now

Largest portfolio weights among holders, up to 2.7% (Michael Krensavage, Krensavage Asset Management). Not free-float ownership.

  1. Michael Krensavage 2.7%

Who owns VNDA

Sorted by value, long equity only, as of 2026 Q2.

History
Michael Krensavage, Krensavage Asset Management 2.7% Hold 1,180,388 $7.2M History
Murray Stahl, Horizon Kinetics Asset Management <0.01% Reduce −4.6% 22,648 $139K History

2 current, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by VNDA's executives, directors and 10% owners in the last 12 months, from their Form 4s

All VNDA insider trades
  • None no insider bought on the open market
  • $241K sold by 1 insider outside a trading plan
  • None no planned (10b5-1) sales
  1. Tage Honore Director
    Sale
    $241K 30,000 shares at $8.03 24% of stake
    Traded Feb 23 Filed Feb 24
    ↗

Also filed in the last 12 months, not counted as buying or selling: 13 stock grants, 5 sales to cover taxes, and 1 gift.

SEC filings

Recent issuer filings from EDGAR, 20 shown.

Filed Form Detail Links
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G — Filing Doc
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
8-K 5.07 Filing Doc
SCHEDULE 13G — Filing Doc
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
DEF 14A Filing Doc
DEFA14A Filing Doc
8-K 5.02,9.01 Filing Doc
8-K 5.02 Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 7.01 Filing Doc
8-K 8.01,9.01 Filing Doc
8-K 5.02,9.01 Filing Doc
10-K Filing Doc
8-K 2.02,9.01 Filing Doc

Source: SEC EDGAR submissions, updated 6 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $192.64M $198.77M $216.1M
Net income $2.51M -$18.9M -$220.47M
Net margin * 1.3% -9.5% -102.0%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $432.95M $438.89M $347.26M
Total non-current assets * $215.49M $217.31M $141.69M
Total assets $648.44M $656.2M $488.95M
Total current liabilities $87.7M $99.98M $145.16M
Total non-current liabilities * $15.83M $17.68M $16.6M
Total equity $544.91M $538.55M $327.19M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations $12.8M -$15.76M -$109.44M
Cash from investing -$12.06M -$17.43M $94.86M
Cash from financing $0M -$0.155M -$2.91M
Net change in cash $0.792M -$33.5M -$17.46M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.